2022
DOI: 10.1016/j.jddst.2022.103712
|View full text |Cite
|
Sign up to set email alerts
|

Recent advances on drug delivery applications of mucopenetrative/mucoadhesive particles: A review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(6 citation statements)
references
References 222 publications
0
6
0
Order By: Relevance
“…, shape, size, charge, hydrophobicity and surface chemistry of the particle as well as pH of the medium. 5,77–79…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…, shape, size, charge, hydrophobicity and surface chemistry of the particle as well as pH of the medium. 5,77–79…”
Section: Resultsmentioning
confidence: 99%
“…76 As previously claimed in many studies that the particle diffusion in mucus and their subsequent absorption by intestinal cells can be effected by many factors i.e., shape, size, charge, hydrophobicity and surface chemistry of the particle as well as pH of the medium. 5,[77][78][79] Size of the GNLs was observed to be 300 nm after two hours of intestinal digestion, however size of the uncoated liposomes was around 100 nm (Fig. 3A).…”
Section: Food and Function Papermentioning
confidence: 99%
“…30 In addition, nanocarriers are not strong enough to resist the flushing effect of urine, limiting their residence time in the bladder and reducing their effectiveness. 31 Hydrogel, a threedimensional cross-linked network, 32 has good biocompatibility and biodegradability, 33,34 and can effectively trap therapeutic agents. In addition, hydrogels have lower toxicity than nanocarriers.…”
Section: Current Approaches and Advances For Intravesical Instillatio...mentioning
confidence: 99%
“…Whereas various biological barriers in the gastrointestinal tract hinder the clinical development of oral INS [ 4 ], oral INS delivery has to overcome these physiological barriers. First, orally delivered INS should avoid degradation by gastrointestinal enzymes and be stable over a wide pH range (gastric pH 1–3, enteral pH 6–7.5) [ 5 ]. Secondly, as a biomacromolecule, INS cannot directly enter the blood circulation through the intestinal mucosa, nor can it be straight internalized by intestinal epithelial cells into the blood [ 6 ].…”
Section: Introductionmentioning
confidence: 99%